Alan H. Cohen, MD

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat OTC deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

Seasoned medical professional with 30+ years of direct patient-care experience and 17+ years of Biotech/Pharma experience including Clinical Operations/Development (Phase 1-4), Medical Affairs, Executive-level management roles (SVP, CMO etc) leading both small and large teams in start-up as well as Big Pharma work setting. Available for consulting for your start-up, small, mid-sized or large company. Available for consulting opportunities, let me know how I can be of help to you and your team(s).

4DMT is a clinical stage Biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market diseases. We use our transformative vector discovery platform, termed Therapeutic Vector Evolution, to create customized and proprietary gene delivery vehicles to deliver therapeutic payloads to specific tissue types associated with the underlying disease via the optimal route of administration. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capacity to revolutionize genetic medicines and strive for potential curative therapies.

I have served as a Clinical Advisory Board member since 2007 to Aridis Pharmaceuticals, with a transitional leadership role as SVP of Clinical & Medical Affairs from 7/17 to 3/18. My role as Clinical Advisory Board Member resumed in Q1 2018.

Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines and can be leveraged by partners. Our goal is to revolutionize gene editing for the benefit of patients around the world.

Eidos Therapeutics is a BridgeBio Pharma company focused on addressing the large and growing unmet medical need caused by transthyretin (TTR) amyloidosis (ATTR). Eidos is developing acoramidis (AG10), a potentially disease-modifying therapy for the treatment of ATTR-CM (cardiomyopathy). There is significant medical need in ATTR given the large patient population and limited current standard of care. ATTR is caused by the destabilization of TTR due to inherited mutations or aging and is commonly divided into three distinct categories: wild-type ATTR cardiomyopathy (ATTRwt-CM), mutant ATTR cardiomyopathy (ATTRm-CM), and ATTR polyneuropathy (ATTR-PN). The worldwide prevalence of each disease is approximately 400,000 patients, 40,000 patients and 10,000 patients, respectively. All three forms of ATTR are progressive and fatal.

I served as Global Clinical Leader, Pediatrics/Orphan Diseases at Bayer - with a focus on Phase 1-3 clinical trials, as well as translational research programs in novel areas of unmet medical need.

Brace Pharma Capital is a U.S. strategic investment company created by EMS S/A, the largest pharmaceutical company in Brazil. We invest in innovative therapies for diseases with high unmet medical needs and insufficient treatment options, including orphan diseases. Our goal is to develop, obtain market authorization and commercialize safe and effective innovative products through partnerships with R&D companies. They shut down their MD/US offices in Q4 2019.

Clinical Practice in Pediatric Pulmonary Medicine at Lucille Packard Children's Hospital: including the management and care of children with cystic fibrosis, asthma, premature lung disease, recurrent respiratory infections, lung transplantation, interstitial lung disease, sleep medicine etc

Publicly traded (NASDAQ - ARDS) as of 8/2018 - clinical stage bio/pharma company focused on a novel anti-infective platform of biologics and small molecules targeting life-threatening bacterial pathogens. I had previously served as a Clinical Advisory Board member for Aridis from July 2007 through June 2017 before being asked to transition into this FT role and since March/April 2018 I have now resumed my role as a member of Aridis’ Clinical Advisory Board.